Dobrzanski P, Hoeveler A, Doerfler W
Institute of Genetics, University of Cologne, Federal Republic of Germany.
J Virol. 1988 Nov;62(11):3941-6. doi: 10.1128/JVI.62.11.3941-3946.1988.
Studies on the biochemical mechanism of promoter inhibition or inactivation by sequence-specific promoter methylations necessitated the development of a cell-free transcription system that responded to in vitro promoter methylations. Such systems were hitherto not available. In nuclear extracts from HeLa cells, the activities of two adenovirus type 2 promoters in the nonmethylated and methylated forms were compared. The late E2A promoter in vitro methylated at three 5'-CCGG-3' (HpaII) sequences at nucleotides -215, +6, and +24, or the major late promoter in vitro methylated at nucleotide -52 in the 5'-CCGG-3' sequence or at nucleotide -13 in the 5'-GCGC-3' (HhaI) sequence exhibited strikingly lower activities than did the nonmethylated constructs or exhibited no activity at all. The designated nucleotide positions were calculated relative to the cap sites of the two promoters. Upon in vitro transcription, the methylation pattern of the E2A late promoter was shown to be stable. For the inhibitory effects by sequence-specific methylations to be elicited, circular templates had to be used, the DNA titers had to be at critical levels for each extract, and high protein concentrations had to be maintained. When a template mixture of the nonmethylated major late promoter and the 5'-CCGG-3' methylated late E2A promoter of adenovirus type 2 DNA was used, the major late promoter was active and the methylated late E2A promoter was inhibited or inactivated. Activity levels of the two different promoters could be assessed simultaneously in the same assay due to differences in lengths between the products of transcription from the late E2A and major late promoters. Thus inhibition in the cell-free system could be proven to be specific for the methylated promoter. We are currently pursuing the hypothesis that cellular factors are crucial in recognizing methylated promoters and somehow participate in their inactivation.
对序列特异性启动子甲基化导致启动子抑制或失活的生化机制的研究,使得开发一种能对体外启动子甲基化作出反应的无细胞转录系统成为必要。迄今为止,此类系统尚不存在。在从HeLa细胞提取的核提取物中,比较了两种2型腺病毒启动子非甲基化和甲基化形式的活性。晚期E2A启动子在核苷酸-215、+6和+24处的三个5'-CCGG-3'(HpaII)序列处进行体外甲基化,或者主要晚期启动子在5'-CCGG-3'序列的核苷酸-52处或5'-GCGC-3'(HhaI)序列的核苷酸-13处进行体外甲基化,与未甲基化的构建体相比,其活性显著降低,或者完全没有活性。指定的核苷酸位置是相对于两个启动子的帽位点计算的。体外转录时,E2A晚期启动子的甲基化模式显示是稳定的。为了引发序列特异性甲基化的抑制作用,必须使用环状模板,每种提取物的DNA浓度必须处于临界水平,并且必须维持高蛋白浓度。当使用2型腺病毒DNA的未甲基化主要晚期启动子和5'-CCGG-3'甲基化晚期E2A启动子的模板混合物时,主要晚期启动子具有活性,而甲基化晚期E2A启动子被抑制或失活。由于晚期E2A启动子和主要晚期启动子转录产物长度不同,在同一次测定中可以同时评估两种不同启动子的活性水平。因此,可以证明无细胞系统中的抑制作用对甲基化启动子具有特异性。我们目前正在探讨一个假说,即细胞因子在识别甲基化启动子并以某种方式参与其失活过程中起着关键作用。